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Abstract. Background: Haemorrhagic cystitis (HC) is a severe complication occurring after 
haematopoietic stem cell transplantation (HSCT) in 13-40% of patients, caused by infectious 
and/or non-infectious factors that increase the in-hospital length of stay and the risk of mortality 
of transplanted recipients. Although different management interventions have been suggested in 
the literature, available knowledge on interventions performed by Italian nurses in their daily 
practices has not been documented to date. 
Aim of the study: The aim of this study is to describe HC preventive and treatment interventions 
in patients undergoing HSCT as performed by Italian nurses in their daily practice. 
Material and methods: A multicentre survey was conducted in 2018 by inviting all 110 Italian 
HSCT centres belonging to the Italian Group for Bone Marrow Transplantation (GITMO). Data 
collection was performed with an online questionnaire submitted to GITMO reference nurses 
working in each HSCT centre. Descriptive statistics were performed. 
Results: A total of 38 Italian centres participated. The preventive intervention most applied in 
daily care was the mesna administration (n=37; 97.4%), followed by intravenous hyperhydration 
(n=33; 86.8%) and forced diuresis with furosemide (n=24; 63.1%). Preventive continuous 
bladder irrigation (CBI) was performed in 13 centres (34.2%). Transfusions of blood products 
(n=32; 84.2%), CBI (n=31; 81.6%) and intravenous hydration (n=28; 73.7%) were the most 
applied treatments, beyond the administration of analgesics (n=38; 100.0%) and antispasmodics 
(n=26; 68.4%). 
Conclusion: A great variability both in the HC prevention and treatment interventions applied 
in daily practice across centres have emerged suggesting that no strong recommendations in the 
field are available to date. Therefore, there is a need to increase the evidence available in the 
field by providing methodological studies of higher quality, multicentre and prospective. 
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Introduction. In patients undergoing haematopoietic stem cell transplantation (HSCT), haemorrhagic 
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cystitis (HC) is a severe complication with an 
estimated incidence of 13% to 40%.1–4 Infectious 
and/or non-infectious factors contribute to HC 
occurrences, such as adenovirus (ADV) or BK 
polyomavirus (BKPyV) reactivation,5,6 conditioning 
regimens,4,7 graft-versus-host disease (GVHD),2,8 and 
the stem cell sources or donor-recipient 
incompatibility.1,9 HC is responsible for the bleeding 
from the bladder mucosa and a widespread 
symptomatology including burning, bladder pain, and 
severe haematuria with clots retention with possible 
renal failure.10 HC has been classified as early-onset 
(EOHC) when it occurs within 48 hours after the 
conditioning regimens, or late-onset (LOHC) when it 
occurs after 48 hours.11 Moreover, HC has been 
documented to increase the in-hospital length of stay 
and the risk of mortality.3,6 
As emerged from a recent scoping review,12 urine 
alkalinisation, hyperhydration and forced diuresis have 
been the most recommended preventive HC 
measures;1,2 however, conflicting data have been 
reported regarding the effectiveness of the preventive 
application of the continuous bladder irrigation 
(CBI).1,2,13 The agent 2-mercaptoethanol sodium 
sulphonate (mesna) has been documented to reduce the 
urothelial exposure to chemotherapy, particularly 
cyclophosphamide.1,2,13 Even ciprofloxacin as a 
prophylactic measure has been reported to be effective 
in reducing the incidence of severe BKPyV-associated 
haemorrhagic cystitis (BKPyV-HC).14 
Regarding the HC treatment, no gold standard has 
been established to date; however, cidofovir (CDV) 
seems to be the most effective against BKPyV-HC.15–18 
Mackey (2012)19 has demonstrated the use of 
intravesical CDV as capable of limiting the risk of 
renal damage, compared to its intravenous 
administration. Other promising antivirals against 
ADV or cytomegalovirus (CMV)-associated HC have 
also been documented.18,20 Moreover, in cases of 
refractory HC, the administration of intravesical 
prostaglandins has been suggested21,22 in addition to 
local therapies, e.g., formalin and alum,23 hyaluronic 
acid,24 and fibrin glue.25 Furthermore, recent studies 
have suggested the administration of specific T-
BKPyV cells as a new therapeutic option to treat HC 
and to minimise the risks of GVHD,26,27 while 
cystoscopies, cauterisations and surgical interventions 
have been found as useful in severe grades of HC or 
life-threatening conditions.21,28 Supportive measures 
such as CBI, analgesics and blood products have also 
been suggested.15,19,21,22,28 However, which preventive 
or treatments are daily performed at the bedside have 
been rarely documented. Cesaro, on behalf of the 
ECIL-6 working group (2018),29 has recently updated 
the Guidelines for the Management of BKPyV-
associated HC in HSCT recipients; nevertheless, no 
recommendation above grade C (=marginal support for 
use) has been established in the field of HC treatment. 
To date, only three surveys30,31,32 have been 
published on this subject. Gargiulo et al. (2014)32 in 
their prospective study among 30 Italian HSCT centres 
reported an overview of interventions applied by Italian 
nurses and physicians in paediatric and adult 
transplanted patients. As reported by the involved 
experienced professionals, quinolones (87.3%) 
followed by hyperhydration (85.3%) and urine 
alkalinisation (62.2%) were the most common 
preventive interventions, while the bladder catheter 
insertion was reported by 11.8% of the centres. Among 
treatments, hyperhydration (56.3%), bladder catheter 
placement (56.3%), CBI (27.2%) and CDV (12.7%) 
were the most applied. The survey conducted in 2016 
by Schneidewind et al. (2017)31 was addressed to 
haematologists and urologists among the European 
Bone Marrow Transplantation (EBMT) centres in 
Germany, focusing on the management of BKPyV-
associated HC in the adult population by using a 
questionnaire. According to the findings, local bladder 
therapy was the most effective treatment in the opinion 
of 63.3% of haematologists, followed by CDV 
medication (26.7%) and other therapies (10.0%). 
Urologists mainly reported the use of CBI (92.6%) and 
local therapies (27.8%, as cidofovir, leflunomide, 
tranexamic acid and alum), while systemic therapy was 
applied less often (14.8%). More recently, Cesaro and 
colleagues (2018)30 performed a survey on ADV 
infections management in Europe, Russia and the 
Middle East among 89 EBMT centres. CDV was the 
medication most applied. The reduction of 
immunosuppression (84%) and the administration of 
brincidofovir (27%) were largely adopted, especially 
among the paediatric population to treat ADV infection. 
With the intent to advance the available knowledge 
on prevention and treatment as performed in their daily 
practices, the principal aim of this study was to 
describe interventions of Italian clinical nurses to 
prevent and manage HC. A secondary aim was to 
describe the professional experience of nurses in 
managing HC as well as their perceived HC effects on 
patients. 
 
Materials and Methods. A national-wide online 
survey was performed in 2018 involving the Italian 
Group for Bone Marrow Transplantation (GITMO) 
network. Eligible participants were clinical nurses who 
at the time of the survey: (a) were members of GITMO, 
(b) were active clinical nurses in one of the Italian 
HSCT centres included in the GITMO network, and (c) 
were willing to participate in the survey. A total of 110 
clinical nurses were found eligible. 
 
Data collection. A questionnaire was developed by 
researchers in cooperation with the GITMO nurses’ 
board members and piloted by five clinical nurses not 
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involved in this final survey. After the piloting, no 
changes were required. In the questionnaire were 
included all interventions documented in the literature 
which were aimed at preventing and managing HC, as 
emerged from a scoping review.12 The final version of 
the anonymous online survey was based upon 22 items 
divided into the following four sections: 
(1) Section 1: exploring the main demographic 
characteristics of responding nurses, as well as the 
number of HC cases they recalled to have managed 
in 2017, by using closed (n = 3), multiple choice (n 
= 2) and short open-answer questions (8 items), 
(2) Sections 2 and 3: assessing preventive and 
treatment interventions as performed in daily 
practice using multiple-choice questions (n = 3); 
open questions (n = 2) were set regarding timing 
and specification of the interventions applied (e.g., 
administration routes), 
(3) Section 4: exploring nurses’ experiences while 
managing patients with HC (n = 3) regarding (i) 
the encountered difficulties, (ii) the perceived 
impact of HC on patients and (iii) on the nurses, by 
using 5-degree Likert scales (e.g., 1 = no impact, 5 
= maximum impact). Area of investigation and 
items for each area have been established based on 
the available literature12 and the available data 
from the GITMO network, where previous 
research in the field has been conducted. 
Nurses were left free to fill in the questionnaire with 
the support of physicians; only 12 (31.6%) filled in the 
questionnaire autonomously, while the remaining 26 
(68.4%) had the cooperation of a physician working in 
the same centre, as emerged from the last question of 
the questionnaire. 
A presentation letter reporting the aims of the study, 
as well as access instructions and the questionnaire link, 
was sent to all GITMO network centres. The 
completion of the questionnaire was intended as the 
consent to participate in the survey. Two reminders 
were performed by e-mail and by phone to promote 
responses. All procedures were in accordance with the 
ethical standards of the GITMO and with the 1964 
Helsinki Declaration. 
 
Data Analysis. The answers were reported and 
analysed with Microsoft Excel 2013 and then 
processed with the SPSS V 24.00. Descriptive statistics 
were performed (frequencies, percentages, means, 
standard deviations [SD, ±], confidence intervals [CIs] 
at 95%). Open answers were read by two researchers 
and then summarised according to their commonalities 
and differences. 
 
Results. A total of 38 clinical nurses participated, 
mainly caring for adult patients (24; 63.1%). Of the 
110 centres, 34.5% were represented. Most of the 
participants were female (29; 76.3%) with an average  
Table 1. Sociodemographic characteristics of participant nurses 
and HSCT centres (=38). 
Clinical Nurses  N = 38 (%) 
Gender  
Female 29 (76.3) 




Education   
Bachelor’s degree 20 (52.6) 
Diploma of nursing 18 (47.4) 
Working years as nurse in the HSCT 
centre, mean (SD; CI 95%) 
15.8  
(8.3; 13.0–18.5) 
HSCT centre, mission  
Adult  24 (63.2) 
Paediatric  8 (21.0) 
Adult and paediatric  6 (15.8) 
Transplants performed in HSCT 
centres*, total  2,361 
Transplants performed in each HSCT 
centre*, mean (SD; CI 95%) 
62.1  
(37.2; 49.7–74.4) 
Legend: CI: confidence interval; HSCT: haematopoietic stem cell 
transplantation; N: number; SD: standard deviation. 
*according to the data reported by nurses in the questionnaire; 
referred to year 2017. 
 
age of 46.3 ± 8.4 years. The majority of them were 
educated at the university level (20; 52.6%), and at the 
time of the study had been working an average of 15.8 
± 8.3 years, as reported in table 1. 
According to that recalled by participants, an 
average of 62.1 ± 37.2 (range 14–185) transplants were 
performed in 2017. The median number of HC cases in 
the same reference year was 2.4 ± 2.7 (CI 95% 1.5–
3.2), leading to a prevalence rate of 3.8% as reported in 
table 2. The HC cause recalled by clinical nurses was 
mainly infectious (19; 65.5%), such as BK virus (15; 
51.7%). The recalled onset after HSCT was on average 
25.0 ± 27.7 days (ranging from 3–180) and the HC 
duration was 23.7 ± 23.35 days (ranging from 5–150). 
The grading of the common terminology criteria (CTC) 
of the National Cancer Institute (NCI)33 was the most 
used assessment tool for HC (22; 57.9%). In 52.6% of 
centres (n = 20), there were protocols or checklists 
guiding nursing care interventions, as reported in table 
2. 
 
Preventive interventions. In order to prevent HC, the 
most applied intervention reported by nurses was the 
intravenous mesna (37 of 38 centres; 97.4%), followed 
by hyperhydration with normal saline solution (33; 
86.8%) and forced diuresis with furosemide (24; 
63.1%). The placement of a three-way urinary catheter 
to supply CBI was carried out in 13 centres (34.2%). 
The least applied preventive intervention was the oral 
hydration and the placement of the bladder catheter, as 
reported in table 3. Several centres (10; 26.3%) applied 
four preventive interventions per patient, whereas 1 
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Table 2. HC data in the involved Italian HSCT centres (=38). 
Epidemiological data on HC N = 38 (%) 
Cases of HC* 90 
Cases of HC*, mean (SD; CI 95%) 2.4 (2.7; 1.5–3.2) 
HC grading tool used in daily practice  
NCI CTCAE (2017)33 22 (57.9) 
Bedi et al. (1995)34 4 (10.5) 
Sencer et al. (1993)44 1 (2.6) 
Bearman et al. (1988)45 1 (2.6) 
Droller et al. (1982)35 2 (5.3) 
None 8 (21.0) 
Main aetiology of HC* N = 29 (%) 
Infectious 19 (65.5) 
Related to conditioning regimen and 
infections 3 (10.3) 
Related to the conditioning regimen 2 (6.9) 
Acute GVHD 2 (6.9) 
Idiopathic 1 (3.4) 
Related to conditioning regimen and 
acute GVHD 1 (3.4) 
Non-identifiable, multifactorial 1 (3.4) 
Specific aetiology of HC*  
BKV 15 (51.7) 
CY+BKV 4 (13.8) 
CY 1 (3.4) 
CY-BU 1 (3.4) 
BKV+ADV 2 (6.9) 
BKV+JCV 1 (3.4) 
BKV+ADV+JCV 1 (3.4) 
CY-BU-FLU+BKV 1 (3.4) 
CY+BKV+TBI 1 (3.4) 
Unspecified 2 (6.9) 
Estimated onset of HC (days from 
HSCT), mean (SD; CI 95%) 
25.0  
(27.7; 15.9–34.1) 
Estimated duration of HC (days), mean 
(SD; CI 95%) 
23.7  
(23.3; 16.1–31.4) 
HC management protocol available 
at the unit level, yeas 20 (52.6) 
Legend: ADV: adenovirus; BKV: BK virus; BU: busulfan; CI: 
confidence interval; CY: cyclophosphamide; FLU: fludarabine; 
GVHD: graft versus host disease; JCV: JC virus; HC: 
haemorrhagic cystitis; HSCT: haematopoietic stem cell 
transplantation; N: number; SD: standard deviation; TBI: total 
body irradiation. 
*according to the data reported by nurses in the questionnaire; 
referred to year 2017. 
 
 (2.6%), 4 (10.5%), 8 (21.0%), 6 (15.8%), 6 (15.8%) 
and 3 (7.9%) centres have applied one, two, three, five, 
six and seven interventions per patient, respectively. 
Intravenous mesna administration was usually started 
at the beginning of cyclophosphamide (CY) 
administration in more than half of the centres (25 of 
37; 67.6%); five centres specified “at the beginning of 
the conditioning regimen.” The administration ended 
Table 3. HC preventive and treatment interventions as applied by 
nurses in Italian HSCT centres (=38). 
Interventions N = 38 (%) 
Preventive interventions  
Intravenous mesnaa 37 (97.4) 
Intravenous hyperhydration with normal saline 
solutiona 33 (86.8) 
Forced diuresis with furosemide (for diuresis 
contraction or weight increase > 1 kg)a 
24 (63.1) 
 
Urine alkalinisation with sodium bicarbonatea 20 (52.6) 
Three-way intravesical catheter placement and 
CBIa 13 (34.2) 
Intravenous hyperhydration with dextrose 5% 
solutiona 12 (31.6) 
Intravenous ganciclovira 8 (21.0) 
Forced diuresis with frequent voiding 5 (13.1) 
Urine alkalinisation with acetazolamidea 5 (13.1) 
Oral hyperhydration 1 (2.6) 
Other: intravesical catheter placement for 
incontinence or difficulty in emptying the 
bladder in patients with multiple sclerosis 
1 (2.6) 
Other: intravesical catheter emptying during 
treatment with cyclophosphamide 1 (2.6) 
Treatment interventions  
Blood products transfusionsa 32 (84.2) 
3-way bladder catheter placement and CBI 31 (81.6) 
Intravenous hyperhydrationa 28 (73.7) 
Intravenous antiviralsa 27 (71.0) 
Manual irrigation and removal of the clots 27 (71.0) 
Oral medicationsa 13 (34.2) 
Intravenous medicationsa 12 (31.6) 
Oral antiviralsa 11 (28.9) 
Uricosuricsa 10 (26.3) 
Medications through intravesical instillationa 9 (23.7) 
Collaborating/assisting during evacuative 
cystoscopies 9 (23.7) 
+ application of local therapies 6 (15.8) 
+ cauterizations 3 (7.9) 
Interruption of the intravesical catheter’s 
outgoing flow after intravesical medications 7 (18.4) 
Collaborating/assisting during hyperbaric 
oxygen therapy sessions 3 (7.9) 
Target therapiesa 2 (5.3) 
Antivirals through intravesical instillationa 2 (5.3) 
Changing patient’s position after 
administration of intravesical medications 1 (2.6) 
Oral hyperhydration 0 (-) 
Phytotherapeutics 0 (-) 
Legend: CBI: continuous bladder irrigation; HC: haemorrhagic 
cystitis; HSCT: haematopoietic stem cell transplantation; N: 
number. 
aunder physician’s prescription. 
 
at the time of the CY administration (4 of 37; 10.8%) 
and the conditioning regimen in general (3 of 37; 
8.1%), or from 6–48 hours after the last dose of CY (17 
of 37; 45.9%); however, 11 (29.7%) centres did not 
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respond. 
Hyperhydration with normal saline was started from 
the patient admission in the centre to 6 hours before the 
conditioning (10 of 33; 30.3%), or from the beginning 
of the conditioning regimen (11 of 33; 33.3%); three 
participants specified “at the beginning of CY 
administration”. It continued until the end of 
chemotherapy administration in 8 of 33 centres 
(24.2%). However, 10 (30.3%) and 14 (42.4%) of 33 
centres using hyperhydration with normal saline did 
not respond regarding when this preventive measure is 
used to be started and ended, respectively. 
Forced diuresis with furosemide was usually started 
at the beginning of the conditioning regimen in 6 of 24 
centres (25.0%)—three participants specified “at the 
beginning of CY administration”—or at the end of the 
conditioning (2 of 24; 8.3%). The administration of 
furosemide usually ended when the conditioning 
regimen also ended (3 of 24; 12.5%), specifically from 
24–48 hours later (4 of 24; 16.7%). However, also, in 
this case, 14 (58.3%) and 15 (62.5%) centres did not 
respond regarding when this preventive measure is 
used to be started and ended, respectively. 
 
Treatment interventions. As shown in table 3, the most 
applied HC treatment is the transfusion of blood 
products (32; 84.2%), followed by CBI (31; 81.6%) 
and the intravenous hyperhydration (28; 73.7%). 
Manual irrigation and administration of intravenous 
antivirals were reported by 27 centres (71.0%). No 
centres reported the use of oral hyperhydration and 
phytotherapeutics. Several centres applied six or seven 
interventions on the same patient (12 of 38; 31.6%). 
Among transfused blood components, platelets (24 of 
32; 75.0%), packed red blood cells (13 of 32; 40.6%), 
fresh frozen plasma (5 of 32; 15.6%) and albumin (1 of 
32; 3.1%) were reported as being used most often. 
Most centres, to manually irrigate and remove clots, 
used a 50–60 mL syringe by injecting a normal saline 
solution (7 of 27; 25.9%), water for injectable 
preparations (3 of 27; 11.1%) or distilled water (1 of 
27; 3.7%). However, 16 centres (59.2%) did not 
specify the solution used. 
Concerning the CBI, most centres reported using as 
infusing solution the normal saline (10 of 31; 32.2%) 
or water for injectable solutions (3 of 31; 9.7%). One 
centre out of 31 (3.2%) administered CBI using a 
volumetric pump, and 3 (9.7%) reported using 
solutions prepared at a lower temperature than that of 
the environment. Moreover, three centres of 31 (9.7%) 
started the administration at the onset of 
microhematuria or large clots, while one centre (3.2%) 
reported stopping it at haematuria’s resolution. Other 
centres did not report data regarding the timing of CBI 
use. 
The infused solutions for hyperhydration were 
reported as containing normal saline (15 of 28; 53.6%), 
sodium bicarbonate (4 of 28; 14.3%) and dextrose 5% 
(2 of 28; 7.1%). Two centres specified “dextrose 5% 
with potassium chloride corrections” and “electrolysing 
rehydrating solutions”, respectively. 
As antivirals, oral acyclovir (5 of 11; 45.4%), oral 
CDV (11 of 27; 40.7%), intravenous ganciclovir (6 of 
27; 22.2%), intravenous foscavir (9 of 27; 33.3%) and 
intravenous acyclovir (3 of 27; 11.1%) emerged as 
highly used. CDV was given by intravesical instillation 
(2 of 38; 5.3%), interrupting the outflow from the 
bladder catheter for 30 minutes in 3 of 7 centres 
(42.8%) after the end of the instillation. Among other 
medications, ciprofloxacin (8 of 13; 61.5%) and 
levofloxacin, oxybutynin, leflunomide, meropenem, 
ceftazidime (5 of 13; 38.5%) were reported as used by 
oral administration. Among those nurses who reported 
to have supported physicians in evacuative 
cystoscopies (9 of 38; 23.7%), 3 of them (33.3%) have 
applied local fibrin glue while one has applied the 
hyaluronic acid (out of 9; 11.1%) and two the platelet 
gel (out of 9; 22.2%), respectively. Moreover, three 
nurses (7.9%) reported having supported clinicians in 
performing cauterisations. 
Figure 1 shows the medications usually given by 
nurses to relieve pain. The administration of 
intravenous opioid analgesics (31; 81.6%) and of 
antispasmodics by prescription (26; 68.4%) were the 
most applied medications. 
 
Nurses’ experiences. As seen in table 4, the greatest 
difficulty that nurses encountered in the management 
of patients with HC was the large degree of support 
that these patients required to improve their adverse 
emotional state due to this complication (average 3.31 
out of 5; SD 1.16). The lowest difficulty was the 
technical management of urinary devices (1.97 out of 
5; SD 0.97). According to the experience of nurses, the 
highest impact of HC is at the patient level, affecting 
the quality of life (QoL) (4.60 out of 5; SD 0.59). The 
impact on healthcare professional workloads and 
processes was the least (3.50 out of 5; SD 1.06). A 
sense of impotence (2.74 out of 5; SD 1.20), frustration 
(2.58 out of 5; SD 1.48), dissatisfaction (2.47 out of 5; 
SD 1.37) and anxiety (2.26 out of 5; SD 1.29) were the 
most-perceived impacts upon nurses while managing a 
patient with HC. 
 
Discussion. To the best of our knowledge, this is the 
first survey at the national level that included nurses 
and explored the HC preventive and treatment 
interventions as performed in daily practice. The 
majority of them completed the questionnaire with 
physicians, suggesting that in these settings, 
multidisciplinary care is fundamental. Although higher 
than that reported in the EBMT Survey on ADV 
(20%),30 the response rate was low (34.5%) as 
compared to that reported by a German survey
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Figure 1. Applied interventions to relieve HC-associated pain by Italian nurses in HSCT centres (n =38). 
 
Legend: HC: haemorrhagic cystitis; HSCT: haematopoietic stem cell transplantation; n: number. 
 
Table 4. Professional experiences of Italian nurses while managing 
a patient with HC (n=38). 
Investigated items Average, SD 
Encountered difficulties while caring for a 
patient with HC (*) 
 
Supporting the patient with the intent to 
improve his/her psycho-emotional condition 
3.31 (1.16) 
Managing pain and HC-related symptoms  2.71 (1.31) 
Treating HC  2.66 (1.17) 
Managing the functional dependence of 
patients (e.g., bedridden) 
2.42 (0.98) 
Technically managing urinary devices (bladder 
catheter, hand irrigation, instillations) 
1.97 (0.97) 
Perceived impact of HC on outcomes (**)  
Patients’ quality of life  4.60 (0.59) 
Psycho-emotional burden of patients 4.47 (0.69) 
Psycho-emotional burden of the family 4.29 (0.93) 
Nurses workloads 4.00 (0.90) 
Healthcare professional workloads and 
processes 
3.50 (1.06) 
Agreement/disagreement on provided 
statements (***) 
 
“I feel a sense of impotence related to the 
limited availability of effective interventions”  
2.74 (1.20) 
“I feel a sense of frustration while managing 
HC”  
2.58 (1.48) 
“I am dissatisfied with HC management 
outcomes” 
2.47 (1.37) 
“I feel anxiety with regard to possible 
evolution of HC” 
2.26 (1.29) 
Legend: HC: haemorrhagic cystitis; n: number; SD: standard 
deviation. 
(*) 1 = no difficulty, 5 = extreme difficulty. 
(**) 1 = no impact, 5 = maximum impact. 
(***) 1 = completely disagree, 5 = completely agree. 
 (>70%).31 
The prevalence of HC was estimated on the basis of 
the recall of participants – as well as for the HC onset, 
the duration and the aetiology. Prevalence was around 
3.8%, lower than that reported in the literature (19.0%,1 
12.2%,32 32.5%2). However, the centres were 
performing both autologous and allogeneic HSCTs. 
Autologous HSCTs have been less associated with the 
risk of developing HC as compared to allogeneic 
ones.1,13 The large variability reported regarding the 
onset of HC after HSCT, and its duration, have been 
documented as heterogeneous also in the 
literature.31,32,34 However, although data collected were 
reported by nurses with long professional experience 
(>15 years, thus experts in the field), this may not 
reflect the actual data of the centres. 
The most described HC aetiology is related to 
infections (specifically to BKPyV). This could be 
attributed to the advances in prophylaxis against the 
urotoxic effects with the conditioning regimens and to 
the more known role of BKPyV and other viruses as 
risk factors as documented in the recent literature 
mainly focused upon the viral HCs.6,15,19,31 The role of 
busulfan-cyclophosphamide as a risk factor for HC was 
not confirmed by the multivariate analysis of Tsuboi et 
al. (2003).4  
The CTC of NCI33 in its many versions has been the 
most applied assessment tool in the haematological 
centres involved, and several authors21,26 used this 
classification. However, Gargiulo et al. (2014)32 used 
the score developed by Droller and colleagues (1982),35 
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which was adopted by only two centres in our survey. 
Increasing comparability of the data in future 
multicentre studies by applying a common assessment 
tool is recommended. 
 
Preventive interventions. The most applied preventive 
intervention is the administration of mesna as reported 
by several studies.1,2,13 Its administration is more 
common compared to Gargiulo and colleagues’ data 
(2014),32 where mesna was administered in 50.6% of 
patients. However, fluoroquinolones that Gargiulo et al. 
(2014)32 reported as the most applied intervention were 
not administered in our survey. Rather, the use of 
quinolones such as ciprofloxacin (8; 21.0%) and 
levofloxacin (1; 2.63%) has been considered as 
therapeutic measures. After Leung et al. (2005),36 
Miller et al. (2011)14 administered ciprofloxacin 500 
mg orally every 12 hours until 60 days after HSCT in 
44 patients (48 patients did not receive prophylaxis) 
showing a cumulative incidence of HC of 2.6% in the 
ciprofloxacin group as compared to 20.9% in the non-
treated group (P=0.01). Thus, they demonstrated that 
ciprofloxacin was effective in reducing the incidence of 
severe BKPyV-HC. 
From the 37 centres administering mesna, some 
centres preferred intermittent intravenous boluses and 
some preferred continuous infusion. From the scoping 
review by Visintini et al. (2019),12 mesna can be 
administered by intermittent boluses2,34 or by 
continuous infusion.13 Large variability of practices 
exists concerning when the mesna should be started 
and ended. Conflicting data has also emerged, thus 
causing uncertainty and the absence of standard care 
plans. Hadjibabaie et al. (2008)2 administered mesna 
before CY infusion and every 6 hours for a total of 
three doses and Vose et al. (1993)13 tested mesna 
administration from 1 hour before CY, by continuous 
infusion, until 24 hours after the last CY dose. Bedi et 
al. (1995)34 conducted a randomised controlled trial 
among 147 American HSCT recipients with HC. Their 
regimen consisted of 5 intravenous doses at 30 min 
before CY and 3, 6, 9 and 12 hours after each dose of 
CY. 
As the second- and third-most applied preventive 
interventions, hyperhydration with normal saline and 
forced diuresis with furosemide have both been 
recommended for the prevention of HC.34 An 
administration speed of 250 mL/h was used in the 
randomised controlled trial by Vose et al. (1993),13 
while 2500 mL/day emerged from the retrospective 
analysis of Gonella et al. (2015).1 Bedi and colleagues 
(1995)34 preferred 2 mL/kg/h until 24 hours after the 
last CY dose. Dextrose water and normal saline 
containing potassium chloride have also been utilised.2 
According to our data, only one Italian centre reported 
the use of oral hyperhydration, a natural way to intake 
fluids but probably more uncomfortable for patients, 
considering the quantity of daily water to drink (at least 
2 L). In addition, forced diuresis with furosemide was 
tested by Bedi et al. (1995)34 as compared to mesna and 
findings showed equally preventive effectiveness of 
both interventions (P=0.41). Forced diuresis through 
frequent voiding has not been documented by studies 
available as effective in reducing HC as compared to 
CBI.37,38 
Data about the effectiveness of preventive CBI are 
still conflicting.1,2,13 However, 13 centres have reported 
using it in daily care. Gonella et al. (2015)1 suggested 
considering the benefits and harms of preventive 
catheterisation and CBI, especially concerning patients’ 
discomfort and an increased risk of urinary tract 
infections. Moreover, according to the recent ECIL 6 
Guidelines (2018)29 the prophylaxis of BKPyV-HC 
relying on hyperhydration and bladder irrigation, in 
particular when using myeloablative conditioning 
based on CY or other alkylating agents, have been 
suggested with low levels of evidence and strength of 
recommendations (hyperhydration=BII, level of 
evidence from at least one well-designed clinical trial, 
moderately recommended for use; bladder irrigation; 
CII=level of evidence from at least one well-designed 
clinical trial without randomization, marginally 
recommended for use). Furthermore, the use of specific 
antivirals and fluoroquinolones have not been 
recommended (DII). 
 
Treatment interventions. The administration of blood 
products has been the most applied treatment for HC. 
Actually, it is considered a supportive treatment, able 
to improve HC but not effective alone in its 
resolution.15,21,34,38,39 However, blood transfusions could 
be supportive not only for HC but even for the 
myeloablative effects of chemotherapies, and their 
common use can be considered a standard of care in 
patients undergoing HSCT. Bladder catheter placement 
and CBI have emerged as being widely used. Gargiulo 
et al. (2014)32 divided the catheter placement (56.3%) 
from the CBI (27.2%), and therefore our data could not 
be compared. Only one centre reported using a 3-way 
bladder catheter. However, the documented 
effectiveness of CBI1,15,40 has been studied in 
association with other interventions such as the 
instillation of hyaluronic acid.24 
Local therapies have been reported as the most up-
to-date therapeutic measures by urologists (92.6%) and 
haematologists (63.3%).31 From our survey, the 
administration of intravesical antivirals was reported 
by only 2 centres using CDV, while 7 reported 
instillations of hyaluronic acid. Local treatments have 
been used rarely in Italy until 2014 (CDV instillation, 
3.6%; hyaluronic acid instillation, 5.5%).32 However, 
intravesical CDV might be an option for symptomatic 
improvement in patients with BKPyV-HC, without 
systemic adverse effects such as renal failure.19 
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Furthermore, 7 centres (18.4%) reported interrupting 
the catheter’s outgoing flow at the end of intravesical 
instillation while 3 interrupted it for 30 minutes (less 
than the hour suggested in the literature).21,39 Moreover, 
among the nine centres implementing evacuative 
cystoscopies, around one-third of them applied topical 
fibrin glue at the same time. This measure has been 
studied mainly in Italy: In the pilot study performed by 
Tirindelli and colleagues (2009),25 five patients with 
refractory HC were treated with fibrin glue through an 
endoscopic applicator. The treatment showed a positive 
response in three patients suggesting that fibrin glue 
may be an effective solution for refractory HC. 
Multiple treatments such as intravenous tranexamic 
acid, immunoglobulins, fibrinogen and antithrombin III 
have also been used. According to the literature 
available, CDV—the most frequently reported 
intravenous antiviral—appeared to have the highest 
level of activity against BKPyV-HC.6,15,16,19 However, 
the recent ECIL 6 Guidelines attributed the highest 
level of evidence (II= evidence from uncontrolled 
trials) for CDV that is still recommended as grade C 
(=marginal support for use), due to its uncertainty 
ineffectiveness and best dose schedule.29 Furthermore, 
the access to CDV has been limited in recent years 
according to the rules of importation of the medication 
from abroad and this has certainly influenced its 
adoption across Italian centres. 
In addition to CDV, leflunomide and other therapies 
such as ciprofloxacin and intravenous 
immunoglobulins have been studied by 
haematologists.31 The use of the antivirals ganciclovir 
and foscavir, as described in our study, has also been 
documented in the literature.18 The role of tranexamic 
acid as a haemostatic agent was associated with a high 
risk of thromboembolic events, and it is 
contraindicated in the management of HC.41 In our 
survey, 21.0% of centres reported its administration 
suggesting the need to improve knowledge on its 
negative effects among clinicians through educational 
initiatives. Immunoglobulins, however, appeared safe 
and effective in association with intravesical 
prostaglandin E2.22 These findings reveal a wide range 
of therapeutic tools with no strong recommendations to 
guide the clinical practice. 
Regarding the manual irrigation and removal of the 
clots, a procedure which has been largely reported to 
be used by our centres, only one study based upon a 
randomised controlled trial21 reported to have handily 
removed the clots before carboprost instillation. No 
data emerged from the German survey,31 likely because 
it was addressed to physicians, and this measure is 
performed by nurses. 
Among supportive measures, Ippoliti et al. (1995)21 
and Laszlo et al. (1995)22 administered analgesics and 
antispasmodics to reduce the discomfort and pain 
associated with catheter and intravesical instillations. 
Patients were premedicated with oral oxybutynin with 
or without belladonna (a phytotherapeutic) and opium 
suppositories.21 These interventions confirm the trend 
of our survey: intravenous opioid analgesics and 
antispasmodics were the most used in the daily practice 
of Italian nurses. Moreover, supportive therapies as 
hyperhydration, bladder irrigation, platelet transfusions 
and pain treatment are recommended by the ECIL 6 
Guidelines (AIII) according to the evidence from 
opinions of respected authorities, thus strongly 
recommended for the clinical use.29 
 
Nurses experiences. To date, no studies have been 
published regarding nurses’ perceptions towards 
encountered difficulties while caring for patients with 
HC, nor on perceived outcomes. Helping patient and 
family caregivers to overcome the emotional burden 
emerged as the greatest difficulty encountered by 
nurses, followed by pain and symptom management 
and by the HC treatment itself. Frustration, 
dissatisfaction and anxiety emerged because of the 
perception of impotence. Nurses who stay close to 
these patients need additional support. Management of 
HC has been reported by our participants to increase 
both nurses’ and other health care professionals’ 
workloads. The impact of HC has been reported at the 
patient level mainly as worsening of the QoL according 
to previous literature.42,43 Yasar and Akin (2016),42 in a 
descriptive study including 100 Turkish patients 
undergoing HSCT, reported a moderate change in 
QoL; additionally, transplanted patients reported an 
inability to carry out social activities (23%) or to fulfil 
responsibilities (31%), and reported feeling alone 
(23%). Having “confidence in my nurse” has been 
reported as increasing the overall QoL. However, the 
study was not focused on patients with HC. 
Our national survey is affected by several 
limitations, such as the low response rate that could 
have introduced a selection bias; moreover, we have 
required nurses to report their experience in terms of 
HC occurrence, patients, and both preventive and 
treatment intervention: recall bias can have affected the 
findings. According to the findings, no common 
standard of care is used in daily practice regarding HC 
preventive and treatment measures. Also, similar 
agents can be administered differently (for example, in 
timing and doses); moreover, any differentiation have 
been reported both in preventive and therapeutic 
measures for EOHC and LOHC. This uncertainty and 
the variability in daily practices reflect the limitation in 
preventive and especially treatment options in the field, 
confirmed even at the international level by the recent 
ECIL 6 Guidelines.29 Therefore, to improve this clinical 
field, multicentre prospective clinical studies are 
strongly necessary: interventions based upon the best 
evidence could improve patients’ outcomes as well as 
alleviate the burden on nurses who manage this clinical 
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